Hereditary  ||| S:0 E:11 ||| JJ
angioedema ||| S:11 E:21 ||| NN
:  ||| S:21 E:23 ||| :
a  ||| S:23 E:25 ||| DT
case  ||| S:25 E:30 ||| NN
of  ||| S:30 E:33 ||| IN
near  ||| S:33 E:38 ||| JJ
fatal  ||| S:38 E:44 ||| JJ
laryngeal  ||| S:44 E:54 ||| NNS
swelling  ||| S:54 E:63 ||| VBG
in  ||| S:63 E:66 ||| IN
a  ||| S:66 E:68 ||| DT
41-year-old  ||| S:68 E:80 ||| JJ
woman  ||| S:80 E:86 ||| NN
Hereditary  ||| S:86 E:97 ||| FW
angioedema  ||| S:97 E:108 ||| FW
( ||| S:108 E:109 ||| -LRB-
HAE ||| S:109 E:112 ||| NNP
)  ||| S:112 E:114 ||| -RRB-
is  ||| S:114 E:117 ||| VBZ
characterized  ||| S:117 E:131 ||| VBN
by  ||| S:131 E:134 ||| IN
nonpitting ||| S:134 E:144 ||| NN
,  ||| S:144 E:146 ||| ,
nonpruritic  ||| S:146 E:158 ||| JJ
subcutaneous ||| S:158 E:170 ||| NN
,  ||| S:170 E:172 ||| ,
or  ||| S:172 E:175 ||| CC
submucosal  ||| S:175 E:186 ||| JJ
edema  ||| S:186 E:192 ||| NN
that  ||| S:192 E:197 ||| WDT
may  ||| S:197 E:201 ||| MD
be  ||| S:201 E:204 ||| VB
accompanied  ||| S:204 E:216 ||| VBN
by  ||| S:216 E:219 ||| IN
a  ||| S:219 E:221 ||| DT
nonpruritic  ||| S:221 E:233 ||| JJ
serpentine  ||| S:233 E:244 ||| JJ
erythematous  ||| S:244 E:257 ||| JJ
rash ||| S:257 E:261 ||| NN
.  ||| S:261 E:263 ||| .
The  ||| S:263 E:267 ||| DT
swelling  ||| S:267 E:276 ||| NN
in  ||| S:276 E:279 ||| IN
this  ||| S:279 E:284 ||| DT
autosomal  ||| S:284 E:294 ||| JJ
dominantly  ||| S:294 E:305 ||| NN
inherited  ||| S:305 E:315 ||| VBD
disorder  ||| S:315 E:324 ||| NN
is  ||| S:324 E:327 ||| VBZ
mediated  ||| S:327 E:336 ||| VBN
by  ||| S:336 E:339 ||| IN
uncontrolled  ||| S:339 E:352 ||| JJ
localized  ||| S:352 E:362 ||| JJ
bradykinin  ||| S:362 E:373 ||| JJ
production ||| S:373 E:383 ||| NN
.  ||| S:383 E:385 ||| .
The  ||| S:385 E:389 ||| DT
extremities ||| S:389 E:400 ||| NN
,  ||| S:400 E:402 ||| ,
face ||| S:402 E:406 ||| NN
,  ||| S:406 E:408 ||| ,
gastrointestinal  ||| S:408 E:425 ||| JJ
tract ||| S:425 E:430 ||| NN
,  ||| S:430 E:432 ||| ,
genitalia ||| S:432 E:441 ||| NN
,  ||| S:441 E:443 ||| ,
larynx ||| S:443 E:449 ||| NN
,  ||| S:449 E:451 ||| ,
and  ||| S:451 E:455 ||| CC
trunk  ||| S:455 E:461 ||| NNS
are  ||| S:461 E:465 ||| VBP
commonly  ||| S:465 E:474 ||| RB
involved ||| S:474 E:482 ||| VBN
.  ||| S:482 E:484 ||| .
Nearly  ||| S:484 E:491 ||| RB
one-third  ||| S:491 E:501 ||| JJ
of  ||| S:501 E:504 ||| IN
patients  ||| S:504 E:513 ||| NNS
who  ||| S:513 E:517 ||| WP
are  ||| S:517 E:521 ||| VBP
not  ||| S:521 E:525 ||| RB
treated  ||| S:525 E:533 ||| VBN
may  ||| S:533 E:537 ||| MD
suffer  ||| S:537 E:544 ||| VB
asphyxiation  ||| S:544 E:557 ||| VBN
from  ||| S:557 E:562 ||| IN
a  ||| S:562 E:564 ||| DT
laryngeal  ||| S:564 E:574 ||| JJ
attack ||| S:574 E:580 ||| NN
.  ||| S:580 E:582 ||| .
HAE  ||| S:582 E:586 ||| NNP
symptoms  ||| S:586 E:595 ||| NNS
overlap  ||| S:595 E:603 ||| VBP
with  ||| S:603 E:608 ||| IN
other  ||| S:608 E:614 ||| JJ
conditions  ||| S:614 E:625 ||| NNS
that  ||| S:625 E:630 ||| WDT
cause  ||| S:630 E:636 ||| VBP
swelling ||| S:636 E:644 ||| VBG
.  ||| S:644 E:646 ||| .
An  ||| S:646 E:649 ||| DT
accurate  ||| S:649 E:658 ||| JJ
diagnosis  ||| S:658 E:668 ||| NN
is  ||| S:668 E:671 ||| VBZ
therefore  ||| S:671 E:681 ||| RB
crucial  ||| S:681 E:689 ||| JJ
when  ||| S:689 E:694 ||| WRB
considering  ||| S:694 E:706 ||| VBG
therapy ||| S:706 E:713 ||| NN
.  ||| S:713 E:715 ||| .
Recently  ||| S:715 E:724 ||| RB
approved  ||| S:724 E:733 ||| VBN
treatments  ||| S:733 E:744 ||| NNS
for  ||| S:744 E:748 ||| IN
HAE  ||| S:748 E:752 ||| NNP
swelling  ||| S:752 E:761 ||| VBG
attacks  ||| S:761 E:769 ||| NNS
include  ||| S:769 E:777 ||| VBP
C1  ||| S:777 E:780 ||| RB
esterase  ||| S:780 E:789 ||| JJ
inhibitor  ||| S:789 E:799 ||| JJ
concentrate  ||| S:799 E:811 ||| NN
and  ||| S:811 E:815 ||| CC
ecallantide ||| S:815 E:826 ||| NN
.  ||| S:826 E:828 ||| .
This  ||| S:828 E:833 ||| DT
case  ||| S:833 E:838 ||| NN
describes  ||| S:838 E:848 ||| VBZ
a  ||| S:848 E:850 ||| DT
41-year-old  ||| S:850 E:862 ||| JJ
woman  ||| S:862 E:868 ||| NN
who  ||| S:868 E:872 ||| WP
was  ||| S:872 E:876 ||| VBD
treated  ||| S:876 E:884 ||| VBN
ineffectively  ||| S:884 E:898 ||| VBN
for  ||| S:898 E:902 ||| IN
more  ||| S:902 E:907 ||| JJR
than  ||| S:907 E:912 ||| IN
20  ||| S:912 E:915 ||| CD
years ||| S:915 E:920 ||| NNS
,  ||| S:920 E:922 ||| ,
was  ||| S:922 E:926 ||| VBD
switched  ||| S:926 E:935 ||| VBN
to  ||| S:935 E:938 ||| TO
an  ||| S:938 E:941 ||| DT
effective  ||| S:941 E:951 ||| JJ
therapy ||| S:951 E:958 ||| NN
,  ||| S:958 E:960 ||| ,
but  ||| S:960 E:964 ||| CC
suffered  ||| S:964 E:973 ||| VBN
near  ||| S:973 E:978 ||| IN
fatal  ||| S:978 E:984 ||| JJ
laryngeal  ||| S:984 E:994 ||| NNS
edema  ||| S:994 E:1000 ||| VBP
due  ||| S:1000 E:1004 ||| JJ
to  ||| S:1004 E:1007 ||| TO
a  ||| S:1007 E:1009 ||| DT
missed  ||| S:1009 E:1016 ||| JJ
dose  ||| S:1016 E:1021 ||| NN
of  ||| S:1021 E:1024 ||| IN
the  ||| S:1024 E:1028 ||| DT
effective  ||| S:1028 E:1038 ||| JJ
therapy ||| S:1038 E:1045 ||| NN
.  ||| S:1045 E:1047 ||| .
The  ||| S:1047 E:1051 ||| DT
case  ||| S:1051 E:1056 ||| NN
underscores  ||| S:1056 E:1068 ||| VBZ
the  ||| S:1068 E:1072 ||| DT
need  ||| S:1072 E:1077 ||| NN
for  ||| S:1077 E:1081 ||| IN
increased  ||| S:1081 E:1091 ||| JJ
awareness  ||| S:1091 E:1101 ||| NN
of  ||| S:1101 E:1104 ||| IN
HAE  ||| S:1104 E:1108 ||| NNP
among  ||| S:1108 E:1114 ||| IN
clinicians  ||| S:1114 E:1125 ||| NN
and  ||| S:1125 E:1129 ||| CC
the  ||| S:1129 E:1133 ||| DT
importance  ||| S:1133 E:1144 ||| NN
of  ||| S:1144 E:1147 ||| IN
good  ||| S:1147 E:1152 ||| JJ
compliance  ||| S:1152 E:1163 ||| NN
to  ||| S:1163 E:1166 ||| TO
therapy  ||| S:1166 E:1174 ||| NN
among  ||| S:1174 E:1180 ||| IN
patients  ||| S:1180 E:1189 ||| NNS
with  ||| S:1189 E:1194 ||| IN
HAE ||| S:1194 E:1197 ||| NNP
.  ||| S:1197 E:1199 ||| .
